FibroBiologics, Inc. Common Stock Total Liabilities
FibroBiologics, Inc. Common Stock total liabilities. Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has total liabilities worth $8.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See FBLG defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of FibroBiologics, Inc. Common Stock (2022–2025)
Total liabilities of FibroBiologics, Inc. Common Stock from 2022 to 2025. This chart illustrates how FibroBiologics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
FibroBiologics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Filter Vision Public Company Limited
BK:FVC
|
Thailand | ฿1.32 Billion |
|
Orion Digital Corp.
NASDAQ:ORIO
|
USA | $96.69 Million |
|
Sportshero Ltd
AU:SHO
|
Australia | AU$866.48K |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
USA | $12.38 Million |
|
iMBC Co.Ltd
KQ:052220
|
Korea | ₩9.60 Billion |
|
Renewables Infrastructure Grp
LSE:TRIG
|
UK | GBX2.50 Million |
|
Diversified Gateway Solutions Bhd
KLSE:0131
|
Malaysia | RM72.24 Million |
|
Rifa Ind
KO:000760
|
Korea | ₩64.66 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down FibroBiologics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FBLG asset base.
Liquidity & Leverage Metrics
FibroBiologics, Inc. Common Stock Total Liabilities Ratios Explained
FibroBiologics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 68.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FibroBiologics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of FibroBiologics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.71 Million | +29.73% |
| 2024-06-30 | $10.57 Million | +19.82% |
| 2023-06-30 | $8.82 Million | +401.71% |
| 2022-06-30 | $1.76 Million | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.